Literature DB >> 10524471

Validity of self-reported drug use in chronic pain patients.

D A Fishbain1, R B Cutler, H L Rosomoff, R S Rosomoff.   

Abstract

OBJECTIVE: Previous researchers have reported that in psychiatric populations many patients provide incorrect self-report information on current drug use. Therefore, the purposes of the present study were to determine the percentage of chronic pain patients (CPPs) using illicit drugs (cannabis, cocaine), to determine the percentage of CPPs who provide incorrect self-report drug use information in the psychiatric examination, and to identify some variables that could help in identifying the CPP likely to provide an incorrect drug use history using drug urine toxicologies. DESIGN/SETTING/PARTICIPANTS/OUTCOME MEASURES: Two hundred seventy-four CPP consecutive admissions to a pain facility were psychiatrically examined according to criteria in the Diagnostic and statistical manual of mental disorders (3rd ed., rev; DSM-III-R), with special emphasis on all current drug use. Immediately after the psychiatric examination, all CPPs were asked to consent to urine toxicology. Urine was tested for benzodiazepines, opioids, tricyclics, propoxyphene, cannabinoids, barbiturates, amphetamines, methadone, methaqualone, phencyclidine, alcohol, and cocaine. CPPs were then segregated into three groups: negative toxicology, positive toxicology but concordant with self-report of current drug use, and positive toxicology discordant with self-report of current drug use. These groups were statistically compared with each other with regard to age, gender, race, workers' compensation status, and prevalence of individual DSM-III-R psychoactive substance use disorders. Sensitivities were also calculated for two conditions: accuracy of toxicology and accuracy of self-report.
RESULTS: Toxicologies were obtained from 226 (82.5%) of the CPPs. Toxicologies were negative in 121 (53.5%) and positive in 105 (46.5%) of the CPPs. Of the 226 CPPs, 8.4% had illicit drugs in the urine (6.2% cannabis, 2.2% cocaine). Twenty (8.8%) of the CPPs provided incorrect self-report information about current drug use, the incorrect information most frequently about illicit drugs. Drug urine toxicology sensitivity results indicated that a significant percentage of CPPs was claiming to be taking a drug but was not taking it or taking it incorrectly. The psychiatric examination drug self-report sensitivity results indicated that a significant percentage of CPPs was withholding or providing incorrect information on current drug use. Lowest self-report sensitivity results were in reference to illicit drugs. CPPs who were more likely to provide incorrect psychiatric examination self-report information about current drug use were more likely to be younger, to be a workers' compensation CPP, and to have been assigned a DSM-III-R diagnosis of polysubstance abuse in remission.
CONCLUSIONS: A significant percentage of CPPs appears to provide incorrect information on current illicit drug use. Urine toxicology studies may have a place in the identification of drugs for which incorrect information may be provided by CPPs. There are many possible reasons, such as assay error, that could lead to apparent misinformation. In the clinical setting, these possibilities should be considered if urine toxicology results appear to be incongruent with psychiatric examination drug use self-report.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524471     DOI: 10.1097/00002508-199909000-00005

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  25 in total

1.  Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors.

Authors:  Kathleen W Saunders; Michael Von Korff; Cynthia I Campbell; Caleb J Banta-Green; Mark D Sullivan; Joseph O Merrill; Constance Weisner
Journal:  J Pain       Date:  2012-01-29       Impact factor: 5.820

2.  Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder.

Authors:  Benjamin J Morasco; Susan Gritzner; Lynsey Lewis; Robert Oldham; Dennis C Turk; Steven K Dobscha
Journal:  Pain       Date:  2010-12-23       Impact factor: 6.961

Review 3.  [Risk factors for substance abuse and dependence in opioid therapy for chronic noncancer-related pain].

Authors:  J Jage; A Willweber-Strumpf; C Maier
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

4.  Evaluation and comparison of tools for diagnosing problematic prescription opioid use among chronic pain patients.

Authors:  Merav Kovatch; Daniel Feingold; Odelia Elkana; Shaul Lev-Ran
Journal:  Int J Methods Psychiatr Res       Date:  2016-10-23       Impact factor: 4.035

5.  Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Authors:  Dayong Lee; Erin L Karschner; Garry Milman; Allan J Barnes; Robert S Goodwin; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-11-10       Impact factor: 4.492

Review 6.  Laboratory testing for prescription opioids.

Authors:  Michael C Milone
Journal:  J Med Toxicol       Date:  2012-12

7.  They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.

Authors:  Joanna L Starrels; Aaron D Fox; Hillary V Kunins; Chinazo O Cunningham
Journal:  J Gen Intern Med       Date:  2012-07-20       Impact factor: 5.128

Review 8.  Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs.

Authors:  Kathryn L Hahn
Journal:  Am Health Drug Benefits       Date:  2011-03

9.  Adherence to clinical guidelines for opioid therapy for chronic pain in patients with substance use disorder.

Authors:  Benjamin J Morasco; Jonathan P Duckart; Steven K Dobscha
Journal:  J Gen Intern Med       Date:  2011-05-12       Impact factor: 5.128

10.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.